Negro Roberto, Greco Gabriele
Department of Internal Medicine, Division of Endocrinology, "V. Fazzi" Hospital, Piazza F. Muratore, 73100, Lecce, Italy.
Endocr Metab Immune Disord Drug Targets. 2019;19(7):1041-1045. doi: 10.2174/1871530319666190206123156.
Laser Ablation (LA) is a therapeutic modality for reducing the volume of large benign thyroid nodules. This retrospective study was aimed at assessing the outcome of LA in patients with benign nonfunctioning thyroid nodules in a 5-years follow-up.
Sixty-two patients (47 females; mean age 54.7±12 yr) with benign cold thyroid nodules underwent LA from July 2009 to March 2012. Nodule volume, thyroid function test, and ultrasound were monitored at baseline, and at 3, 6 and 12 months after the procedure, then annually. After dividing nodules in solid and spongiform, we evaluated unfavourable outcomes: 1) nodule's volume reduction <50%; 2) need for surgery; 3) need for additive LA session (due to nodule re-growth with persistence of cosmetic concern or compressive symptoms).
Baseline volume did not differ between solid and spongiform nodules as well as energy delivered and the number of needles used. Unfavourable outcomes occurred in 24 patients (38.7%). Nineteen/ 24 (79.2%) patients who experienced unfavourable outcomes belonged to the solid nodules group (P<0.01). When considering only those who benefited from LA, the 5-years reduction was 59.7% for solid and 78.6% for spongiform nodules (P<0.05). One/6 patients who underwent surgery (solid nodules group) had a final diagnosis of Follicular Variant of Papillary Thyroid Cancer (FVPTC).
Large solid nodules, unlike spongiform, submitted to LA are characterized by a long-term unfavourable outcome and entail a potential risk of false negative cytologic results.
激光消融(LA)是一种用于缩小大型良性甲状腺结节体积的治疗方式。这项回顾性研究旨在评估LA治疗良性无功能甲状腺结节患者5年随访的结果。
2009年7月至2012年3月,62例(47例女性;平均年龄54.7±12岁)患有良性冷甲状腺结节的患者接受了LA治疗。在基线时以及术后3、6和12个月,然后每年监测结节体积、甲状腺功能测试和超声检查。将结节分为实性和海绵状后,我们评估了不良结果:1)结节体积缩小<50%;2)需要手术;3)需要额外的LA疗程(由于结节复发并持续存在美容问题或压迫症状)。
实性和海绵状结节的基线体积、传递的能量和使用的针数没有差异。24例患者(38.7%)出现不良结果。19/24例(79.2%)出现不良结果的患者属于实性结节组(P<0.01)。仅考虑那些从LA中获益的患者时,实性结节的5年缩小率为59.7%,海绵状结节为78.6%(P<0.05)。1例接受手术的患者(实性结节组)最终诊断为甲状腺乳头状癌滤泡变体(FVPTC)。
与海绵状结节不同,接受LA治疗的大型实性结节具有长期不良结果的特征,并存在细胞学结果假阴性的潜在风险。